Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Dr. Ostrominski discusses new data from ACC 2025 showing that finerenone improves outcomes in HFmrEF/HFpEF across all KDIGO kidney risk categories.
Media formats available
Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.